#1 Clinical Trials Search in Europe

Sym025

Sym025, also known as S095029, is an innovative anti-NKG2A antibody currently being studied in clinical trials for the treatment of advanced cancers. This article will provide an overview of the ongoing research involving Sym025, focusing on its potential applications in gastroesophageal junction/gastric cancer and non-small cell lung cancer (NSCLC). We’ll explore the objectives, eligibility criteria, and potential benefits of these trials, offering valuable insights for patients and healthcare professionals alike.

Table of Contents

What is SYM025?

SYM025, also known as S095029, is a new type of medicine being developed to help treat certain types of advanced cancers. It belongs to a class of drugs called immunotherapies, which work by helping your body’s own immune system fight cancer cells.[1]

How does SYM025 work?

SYM025 is an anti-NKG2A antibody. Antibodies are proteins that your immune system naturally produces to fight infections and other harmful substances in your body. SYM025 is a specially designed antibody that targets a specific protein called NKG2A.

NKG2A is found on certain immune cells and can sometimes prevent these cells from attacking cancer. By blocking NKG2A, SYM025 may help “take the brakes off” your immune system, allowing it to recognize and fight cancer cells more effectively.[1]

What conditions is SYM025 being studied for?

Currently, SYM025 is being investigated for the treatment of two main types of advanced cancers:

  1. Advanced Gastric or Gastroesophageal Junction Cancer: This includes cancers of the stomach or the area where the stomach meets the esophagus (food pipe) that have spread to other parts of the body or cannot be removed by surgery.[1]
  2. Advanced Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer that has either spread to other parts of the body or cannot be treated with surgery or radiation therapy alone.[2]

In both cases, the studies are focusing on patients whose cancers have specific characteristics that might make them more likely to respond to this type of treatment.

Current Clinical Trials

SYM025 is currently being studied in two main clinical trials:

  1. Gastric/Gastroesophageal Junction Cancer Trial: This study is looking at how safe and effective SYM025 is when combined with another immunotherapy drug called pembrolizumab. It’s for patients with advanced gastric or gastroesophageal junction cancer that has specific genetic features (called MSI-H/dMMR).[1]

  2. Non-Small Cell Lung Cancer Trial: This study is testing SYM025 in combination with another immunotherapy drug called cemiplimab. It’s for patients with advanced NSCLC who have not had any previous treatment for their advanced cancer and whose tumors have high levels of a protein called PD-L1.[2]

Both of these trials are in early phases, which means researchers are still learning about how the drug works, what the right dose might be, and what side effects it might cause.

Potential Benefits and Side Effects

While it’s too early to know for sure how effective SYM025 will be, the hope is that it will help shrink tumors or slow down cancer growth in patients with these advanced cancers. The researchers will be measuring things like how many patients’ tumors shrink (called “objective response”), how long the benefits last, and how long patients survive.[1][2]

As with any new medication, there may be side effects. The clinical trials are carefully monitoring patients for any adverse reactions. Some possible side effects of immunotherapies can include fatigue, skin reactions, and inflammation in various parts of the body. However, the specific side effects of SYM025 are still being studied.[1][2]

Conclusion

SYM025 represents an exciting new approach in cancer treatment. By helping the immune system recognize and fight cancer cells, it may offer hope for patients with advanced gastric, gastroesophageal junction, or non-small cell lung cancers. However, it’s important to remember that this drug is still in the early stages of testing. More research is needed to fully understand its effectiveness and safety. If you think you might be eligible for one of these clinical trials, talk to your doctor about whether it might be an option for you.

Aspect Details
Drug Name Sym025 (S095029)
Drug Type Anti-NKG2A antibody
Administration Intravenous (IV) infusion
Cancer Types Studied Advanced gastroesophageal junction/gastric cancer, Non-small cell lung cancer (NSCLC)
Trial Phases Phase 1b/2
Combination Therapies Pembrolizumab, Cemiplimab
Primary Objectives Safety, tolerability, antitumor activity
Secondary Objectives Pharmacokinetics, immunogenicity, efficacy measures (e.g., response duration, survival)
Key Eligibility Criteria Advanced/metastatic cancer, specific biomarker status (e.g., MSI-H/dMMR, high PD-L1 expression), limited prior treatment

FAQ

  • What is Sym025 and how does it work? Sym025, also known as S095029, is an anti-NKG2A antibody. It works by targeting the NKG2A receptor, which is involved in regulating immune responses. By blocking this receptor, Sym025 aims to enhance the immune system's ability to fight cancer cells.
  • What types of cancer are being studied with Sym025? Sym025 is currently being studied in clinical trials for advanced gastroesophageal junction/gastric cancer and non-small cell lung cancer (NSCLC). These trials focus on patients with specific characteristics, such as MSI-H/dMMR status for gastric cancer and high PD-L1 expression for NSCLC.
  • How is Sym025 administered to patients? Sym025 is administered as a solution for intravenous (IV) infusion. In the clinical trials, it is typically given in combination with other immunotherapy drugs, such as pembrolizumab or cemiplimab, on a specific schedule determined by the study protocol.
  • What are the main objectives of the Sym025 clinical trials? The main objectives of these trials are to evaluate the safety, tolerability, and antitumor activity of Sym025 when used in combination with other immunotherapy drugs. Researchers are also studying its pharmacokinetic profile, immunogenicity, and efficacy in terms of tumor response and patient survival.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary depending on the specific trial. Generally, participants must have advanced or metastatic cancer of the studied type, meet certain biomarker requirements (such as MSI-H/dMMR status or high PD-L1 expression), and have not received extensive prior treatment. Other factors, such as age, overall health status, and absence of certain medical conditions, are also considered.

Ongoing Clinical Trials on Sym025

  • Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Hungary Italy Romania +1

  • Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Hungary Italy +1

Glossary

  • Sym025 (S095029): An investigational anti-NKG2A antibody being studied for the treatment of advanced cancers.
  • NKG2A: A receptor found on certain immune cells that can inhibit their ability to fight cancer. Sym025 targets this receptor to potentially enhance the immune response against tumors.
  • MSI-H/dMMR: Microsatellite Instability-High/Deficient Mismatch Repair, a characteristic of some tumors that may make them more responsive to certain immunotherapies.
  • PD-L1: Programmed Death-Ligand 1, a protein found on some cancer cells that can help them evade the immune system. High PD-L1 expression may indicate a better response to certain immunotherapies.
  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer being studied in clinical trials with Sym025.
  • Gastroesophageal junction cancer: Cancer that forms in the area where the esophagus joins the stomach.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Pharmacokinetic (PK) profile: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • iRECIST: Immune Response Evaluation Criteria in Solid Tumors, a modified version of RECIST used specifically for immunotherapy treatments.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Recommended Phase 2 dose (RP2D): The dose of a drug determined to be safe and effective for further study in Phase 2 clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-activity-of-s095029-and-pembrolizumab-for-patients-with-advanced-gastric-or-gastroesophageal-junction-cancer/
  2. http://clinicaltrials.eu/trial/study-of-sym024-sym023-and-sym025-in-adults-with-advanced-non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression/